This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Overall, the AIM All-Shares index had a positive week, with a more than 2% increase in share price, outperforming the FTSE 100. Friday’s closing bell, the FTSE 100 resumed its
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Block Energy plc, the exploration and production company focused on Georgia, is pleased to announce that it has entered into a Memorandum of Understanding (“MoU”) with the Ministry of Economy
Termination of Salary Sacrifice
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Block Energy plc, the exploration and production company focused on Georgia, announces completion of the farm-out of part of licence XIB to Georgia Oil and Gas Limited (“GOG”).
OKYO Pharma (OKYO), an ophthalmology-focused bio-pharmaceutical company, announced that its GMP packaged OK-101 drug to be used in the upcoming Phase 2, first-in-human, clinical trial in patients with DED, which
Block Energy plc, the exploration and production company focused on Georgia, announces initial results from the WR-B01Za well, part of the initial development phase of the West Rustavi/Krtsanisi Field, the
Block Energy Plc, the exploration and production company focused on Georgia, is pleased to announce a new Corporate Presentation has been published on the Company’s website.
Panther Metals (PALM) the company focused on mineral exploration in Canada, reported the results from the latest round of diamond drilling has confirmed the discovery of an additional volcanogenic massive
2023 already looks like it will be the year for life sciences companies. Poolbeg Pharma (POLB), a biopharmaceutical company, announced the strategic expansion of POLB 001 into oncology.